New pill aims to keep kidneys working longer in millions with CKD
NCT ID NCT06866236
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This study tests a new drug, QRX3, in 3,000 adults with chronic kidney disease (CKD) whose kidney function is declining. The goal is to see if QRX3 can slow that decline and reduce protein in the urine. Participants must have an eGFR below 60 and a slow rate of decline (less than 20% over the past year). The drug targets a cell process called NAD oxidase to help kidneys work better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Neukidney Inc
Pasedena, Texas, 77504, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.